Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In an RWE group proposing a post-marketing study instead of a new RCT, 505(b)(2) literature-to-product bridge table is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. RWE evidence-strategy director has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance close using 505(b)(2) literature-to-product bridge table.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a literature paper the 505(b)(2) package leans on getting retracted for RWE evidence-strategy director. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to drop a secondary turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.